



# Biotech Daily

Thursday December 22, 2022

*Daily news on ASX-listed biotechnology companies*

## FDA Okays Actinogen 6-Months Xanamem Phase IIb Alzheimer's Trial

### [ACTINOGEN MEDICAL](#)

Actinogen says the US Food and Drug Administration has agreed to its 330-patient, six-month, phase IIb trial of Xanamem for early stages of Alzheimer's disease.

Actinogen said that the placebo-controlled, randomized phase IIb trial would evaluate the efficacy of 5mg or 10mg Xanamem versus placebo, daily, on attention and working memory scales including the clinical dementia rating scale, and the Cogstate computerized test battery.

The company said the trial would begin by July 2023, with results expected in 2024.

Actinogen chair Dr Geoff Brooke said the FDA approval of the phase IIb Alzheimer's trial was "a significant milestone for the company".

"This is a testament to the expertise of our management team, advisors and clinical investigators around the world," Dr Brooke said.

Actinogen was up 0.2 cents or 2.1 percent to 9.8 cents.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053  
email: [editor@biotechdaily.com.au](mailto:editor@biotechdaily.com.au); [www.biotechdaily.com.au](http://www.biotechdaily.com.au); twitter: @biotech\_daily